Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
crizotinib (xalkori) (1 trial)
fulvestrant (faslodex) (1 trial)
avelumab (bavencio) (1 trial)
palbociclib (ibrance) (1 trial)
Breast Neoplasms (Phase 2)
Carcinoma, Lobular (Phase 2)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Trials (2 total)
Trial APIs (4 total)